Avacta Group PLC
LSE:AVCT
Avacta Group PLC
LSE:AVCT
Price:
44.7 GBX
-1.76%
Market Closed
Updated:
May 13, 2024
Avacta Group PLC
Cost of Revenue
|
Avacta Group PLC
Cost of Revenue Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Avacta Group PLC
LSE:AVCT
|
Cost of Revenue
-£7.3m
|
CAGR 3-Years
-87%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
-20%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cost of Revenue
-£1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Avacta Group PLC's Cost of Revenue?
Cost of Revenue
-7.3m
GBP
-7.3m
GBP
Based on the financial report for Jun 30, 2023, Avacta Group PLC's Cost of Revenue amounts to -7.3m GBP.
What is Avacta Group PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-20%
-20%
Over the last year, the Cost of Revenue growth was -192%. The average annual Cost of Revenue growth rates for Avacta Group PLC have been -87% over the past three years , -52% over the past five years , and -20% over the past ten years .
You don't have any saved screeners yet
